Clinical trials: Glaucoma
Glaucoma, Optic Neuropathy, Ischemic
Neural Conduction Along the Visual Pathways After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases
In the management of glaucoma, as for as in other optic nerve diseases, an important goal of ophthalmologists is represented by the possibility of influencing visual function.
- Conditions
- Glaucoma, Optic Neuropathy, Ischemic, Visual Pathway Disorder, Optic Nerve
- Trial name
- NCT00404729
- Testing
- Citicoline
- Where
- 2 sites in Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fondazione G.B. Bietti, IRCCS
Glaucoma
A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.
To assess the effectiveness of latanoprost 0.005% ophthalmic solution dosed once-daily and timolol 0.5% dosed twice-daily in paediatric subjects of 18 years of age or under who are diagnosed with glaucoma.
- Trial name
- NCT00716859
- Testing
- Timolol, latanoprost
- Where
- 48 sites in United States, Belgium and 18 more
- Volunteers
- 139 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Ocular Hypertension
Long-Term Non-Interventional Latanoprost Study
This is a non-interventional, prospective, longitudinal cohort study. A total of 150 pediatric subjects with glaucoma or elevated intraocular pressure, including 75 latanoprost-treated subjects and 75 non-topical prostaglandin…
- Trial name
- LYNX (NCT01265719)
- Testing
- No intervention other than routine medical care
- Where
- 29 sites in Belgium, Colombia and 12 more
- Volunteers
- 175 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary Open Angle Glaucoma, Primary Angle Closure Glaucoma
Malay Glaucoma Eye Study II Navigation, Mobility and Reading Ability in Primary Glaucoma
With the improvement of health system, the life span of Asians has increased tremendously especially in Malaysia. As an early preparation to be an 'aging country' in 2023, Malaysia needs to prepare infrastructure and policy to…
- Trial name
- MaGESII (NCT04736264)
- Testing
- Visual rehabilitation module: navigation and mobility, Visual rehabilitation module: exercise, Visual rehabilitation module: reading
- Where
- Malaysia
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Universiti Sains Malaysia
Glaucoma, Open-Angle, Ocular Hypertension
Corneal Versus Conjunctival Delivery Using a Delivery Device
Compare the antihypertensive efficacy of three methods for installing Xalatan
- Trial name
- NCT00143429
- Testing
- Xalatan
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Open-Angle, Ocular Hypertension
Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery Device
Compare the antihypertensive efficacy of two methods for instilling Xalatan eyedrops
- Trial name
- NCT00283764
- Testing
- Xalatan
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Open-Angle, Ocular Hypertension
Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada
This descriptive, non-interventional study will collect information on the presence of risk factors in newly diagnosed ocular hypertension and open-angle glaucoma patients in Canada.
- Trial name
- NCT00334750
- Testing
- There is no intervention in this study.
- Where
- 21 sites in Canada
- Volunteers
- 410 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Ocular Hypertension
A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.
To evaluate the steady-state systemic plasma concentrations of latanoprost acid following administration of latanoprost 0.005% (1.5 ug) in pediatric and adult subjects with glaucoma or ocular hypertension.
- Trial name
- NCT00638742
- Testing
- latanoprost
- Where
- 13 sites in United States, Denmark and 4 more
- Volunteers
- 47 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Open-Angle, Ocular Hypertension
A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma
The purpose of this study is to evaluate the effect of latanoprost on intraocular pressure reduction in patients with ocular hypertension or open-angle glaucoma.
- Trial name
- NCT00647101
- Testing
- Latanoprost
- Where
- 176 sites in France
- Volunteers
- 600 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Ocular Hypertension, Open Angle Glaucoma
A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United Kingdom
Study PhXA41 for its non-inferiority compared with timolol in lowering intra-ocular pressure
- Trial name
- NCT00751049
- Testing
- timolol, PhXA41
- Where
- 12 sites in United Kingdom
- Volunteers
- 294 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Open Angle Glaucoma, Ocular Hypertension
A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within Scandinavia
PhXA41 is not inferior to timolol in reducing intra-ocular pressure
- Trial name
- NCT00751062
- Testing
- timolol, PhXA41
- Where
- 13 sites in Denmark, Finland and 2 more
- Volunteers
- 267 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Ocular Hypertension
Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US
Compare the IOP lowering properties of latanoprost, travoprost and bimatoprost
- Trial name
- XLT (NCT00847483)
- Testing
- latanoprost 0.005% ophthalmic solution, Travoprost 004% sterile ophthalmic solution, Bimatoprost .03% sterile ophthalmic solution
- Where
- 40 sites in United States
- Volunteers
- 375 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Ocular Hypertension
Real World Data Study Assessing The Persistency Of Xalacom And The Other Fixed Dose Combination Products, Duotrav And Ganfort, In The United Kingdom
The hypothesis is that there is no difference in persistency between Xalacom and the alternative fixed dose combination products (Duotrav and Ganfort) over a 12 month period.
- Trial name
- NCT01206361
- Testing
- XALACOM, Duotrav, Ganfort
- Volunteers
- 2,015 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary Open Angle Glaucoma, Ocular Hypertension
A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension
The primary objective of this study was to compare the change in intraocular pressure (IOP) of three different doses of latanoprost (75, 100 and 125 ug/ml) to that of the marketed 50 ug/ml dose, in a dose ranging study.
- Trial name
- NCT01379144
- Testing
- latanoprost 75 ug, latanoprost 100 ug, latanoprost 125 ug
- Where
- 25 sites in Australia, Czechia and 6 more
- Volunteers
- 282 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Posterior Vitreous Detachment
Vitreous Detachment and Glaucoma Progression
Posterior vitreous detachment is a common event. With optical coherence tomography, the investigators can precisely follow the stage of posterior vitrous detachment.
- Trial name
- REVEAL (NCT04719871)
- Where
- France
- Volunteers
- 250 people
- Sponsor
- University Hospital, Montpellier
Glaucoma
Phosphodiesterase Inhibitors in Glaucoma Study (PhiGS)
It is commonly known that high eye pressure is associated with glaucoma. However, there is also a theory that poor circulation to the eye is a contributing factor.
- Trial name
- PhiGS (NCT04052269)
- Testing
- Sildenafil 100mg
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Imperial College London
Primary Glaucoma, Glaucoma Suspect
Development of the Glaucoma Visual Functioning Questionnaire-40 and Its Psychometric Properties
The objective of this study is to develop and test the psychometric properties of a self-report questionaire, the Glaucoma Visual Functioning Questionnaire-40 (GVFQ-40), which was designed to measure the difficulty of daily…
- Trial name
- NCT04722861
- Testing
- GVFQ-40
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Primary Congenital Glaucoma
Surgery for Primary Congenital Glaucoma in Neonates
The current study aimed to compare between the long-term surgical outcomes of 3 surgical options (viscotrabeculotomy (VT), visco-circumferential-suture-trabeculotomy (VCST) or combined VT-Trabeculectomy with MMC (VT-Trab) in…
- Trial name
- NCT04709497
- Testing
- viscotrabeculotomy (VT), visco-circumferential-suture-trabeculotomy (VCST) ., combined VT-Trabeculectomy with MMC (VT-Trab).
- Volunteers
- 60 people
- Sponsor
- Mansoura University
Glaucoma, Open-Angle
Glaucoma and Sleep Quality
This study is a observational, prospective, case-control, monocentric study. The main objective is to study the polysomnographic characteristics of sleep in glaucomatous and non-glaucomatous subjects, using data collected in the…
- Trial name
- POLY-GLAUCOMA (NCT04703959)
- Testing
- polysomnography
- Volunteers
- 150 people
- Sponsor
- University Hospital, Grenoble
Open Angle Glaucoma, Ocular Hypertension
SYL040012, Treatment for Open Angle Glaucoma
The purpose of this double-masked, randomized, controlled study is to assess the safety and ocular hypotensive efficacy of four different doses of SYL040012 (bamosiran) eye drops compared to Timolol maleate 0.5% after 28…
- Trial name
- SYLTAG (NCT02250612)
- Testing
- 1 drop of 0.375% SYL040012 (bamosiran), 1 drop of 0.750% SYL040012 (bamosiran), 1 drop of 1.125% SYL040012 (bamosiran)
- Where
- 21 sites in United States, Estonia and 2 more
- Volunteers
- 184 people
- Sponsor
- Sylentis, S.A.